Clive Svendsen, PhD, on Unlocking the Potential of Astrocyte Cell Therapy


The director of the Regenerative Medicine Institute at Cedars Sinai discussed research being conducted with CNS10-NPC-GDNF in multiple indications.

“All your neurons were born before you were because during development, they're all laid down. So, to try and transplant a new neuron in a 6-year-old patient and get it to function normally is really a big challenge. But if you can protect the ones we have, retain your memories, retain those dopamine circuits, retain those motor circuits, that's going to give you a huge boost and maybe prevent degradation.”

The allogeneic human neural progenitor cell therapy CNS10-NPC-GDNFwas well-tolerated and produced GDNF in participants with amyotrophic lateral sclerosis (ALS) according to recent data from a phase 1/2a study (NCT02943850). The therapy is transduced with glial cell line-derived neurotrophic factor (GDNF) and works by differentiating to astrocyte cells to support neurons. No adverse events (AEs) were observed due to surgery or cell transplantation, and preliminary efficacy analyses showed that treated legs showed promising trends of greater limb isometric strength compared to untreated legs of patients with ALS.

CGTLive spoke with principal investigator Clive Svendsen, PhD, professor of medicine and director, Regenerative Medicine Institute, Cedars Sinai, to learn more about the potential of astrocyte cell therapy in ALS and other conditions it is being evaluated in, including retinitis pigmentosa, stroke, Alzheimer disease, and Huntington disease.


Baloh RH, Johnson JP, Avalos P, et al. Transplantation of human neural progenitor cells secreting GDNF into the spinal cord of patients with ALS: a phase 1/2a trial. Nat Med. Published online September 5, 2022. doi:10.1038/s41591-022-01956-3

Recent Videos
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Subhash Tripathi, PhD, on Generating In Vivo CARs With A2-CAR-CISC EngTreg Cells
Luke Roberts, MBBS, PhD, on Challenges in Developing Gene Therapy for Heart Failure
Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Paul Y. Song, MD, the chairman and chief executive officer of NKGen
© 2024 MJH Life Sciences

All rights reserved.